Systemic IgG4-Related Disease (IgG4-RD) is a rare, immune-mediated condition that mimics infection, cancer, and other autoimmune diseases—but behaves very differently. It causes widespread inflammation, fibrosis, and immune cell infiltration across multiple organ systems, often forming tumor-like lesions that can destroy tissues from within.
Misunderstood, Misdiagnosed, but Now Treatable
Though it can affect nearly any organ, IgG4-RD has a pattern—certain areas of the body are more frequently involved and can offer crucial diagnostic clues.
Commonly involved sites include the:
- Pancreas (autoimmune pancreatitis)
- Salivary and lacrimal glands (painless swelling)
- Retroperitoneum (fibrosis, hydronephrosis)
- Kidneys, lungs, bile ducts, or meninges
Left untreated, this disease can result in organ failure, disfigurement, and repeated hospitalizations. But with targeted biologic infusion therapy, we now have the tools to stop it—and in many cases, reverse it.
Cohen Medical Center: Where IgG4-Related Disease Meets Its Match
Cohen Medical Center has become a regional hub for expertly diagnosing and treating IgG4-RD. Here, advanced infusions such as RITUXAN and UPLIZNA are administered under personalized, protocol-driven regimens with physician oversight and real-time laboratory monitoring. Patients referred to the Infusion Center often arrive frustrated, misunderstood, and exhausted from years of inconclusive testing. They leave with a precise diagnosis, a cutting-edge treatment plan, and a renewed sense of direction and hope.
Symptoms That Should Not Be Ignored
Early detection is critical. IgG4-RD should be suspected in patients with:
- Painless, symmetrical gland swelling
- Chronic retroperitoneal fibrosis or ureteral obstruction
- Unexplained pancreatic masses or biliary strictures
- Interstitial lung disease or nodules
- Orbital pseudotumor or proptosis
- Renal dysfunction with abnormal imaging
- Elevated IgG4 levels or abnormal biopsies showing storiform fibrosis
If any of these apply, urgent infusion consultation at the Infusion Center is warranted.
Why UPLIZNA Is a Breakthrough for IgG4-RD
UPLIZNA (inebilizumab-cdon) is a recently approved anti-CD19 monoclonal antibody that takes B-cell targeting to the next level.
- Pharmacologic Class: Anti-CD19 Monoclonal Antibody
- Mechanism: Targets CD19+ B cells, including plasmablasts and plasma cells—the key drivers of IgG4-RD
- Clinical Impact: Reduces disease activity, prevents relapse, and offers new hope for patients unresponsive to other therapies
- Now Available: Administered at Cohen Medical Center with safety protocols and expert monitoring
UPLIZNA offers what traditional therapies cannot: broader immune modulation, deeper B-cell depletion, and longer-lasting results.
Biologic Infusion Therapies Offered at the INFUSION CENTER
1. RITUXAN (rituximab)
- Time-tested, first-line therapy for IgG4-RD
- Targets CD20+ B cells, the upstream immune regulators
- Effective in early-to-moderate disease and initial presentations
- Administered in induction and maintenance cycles at the Infusion Center
2. UPLIZNA (inebilizumab)
- A revolutionary CD19-targeted biologic
- Penetrates deeper into the B-cell pathway than Rituxan
- Ideal for patients with severe, relapsing, or refractory IgG4-RD
- Initiated and followed at the Infusion Center, with comprehensive patient monitoring
Why Our INFUSION CENTER Is the Gold Standard for IgG4-RD Care
Cohen Medical Center is designed for high-complexity autoimmune care. We provide:
- Rapid initiation of RITUXAN or UPLIZNA without hospital delays
- Full workup: labs, imaging review, biopsy coordination
- Onsite lab monitoring for IgG4 levels, complement, and renal/liver markers
- Coordination with nephrology, pulmonology, GI, and radiology when needed
- A calming, supportive, physician-directed infusion environment
- Flexible scheduling and long-term follow-up for disease monitoring
What Our Patients Experience
Patients treated at the Infusion Center often report:
- Dramatic shrinkage of glandular and fibrotic masses
- Reversal of hydronephrosis and preservation of kidney function
- Resolution of orbital pressure and visual symptoms
- Fewer systemic flares and longer remission periods
- Freedom from chronic steroids and invasive surgical procedures
- Renewed vitality, confidence, and peace of mind
Cohen Medical Center: Setting the National Standard in IgG4-RD Infusion Therapy
We treat IgG4-Related Disease the way it deserves to be treated: with speed, precision, and world-class biologic science.
Our Infusion Center offers:
- RITUXAN Infusions for systemic and early-stage disease
- UPLIZNA Infusions for resistant, severe, or relapsing cases
- CD19-based immune modulation with unmatched depth
- Real-time response tracking, flare prevention, and compassionate care
Referrals and Consultations
If you’re a physician with a suspected or confirmed IgG4-RD patient—or if you’re a patient seeking real answers—Cohen Medical Center is ready to help.
- Same-day infusion assessments available
- UPLIZNA now fully integrated into our infusion protocol
- Comprehensive reports sent to referring providers
The Right Diagnosis. The Right Treatment. The Right Time.
Systemic IgG4-RD doesn’t have to steal years of life. It doesn’t have to keep you on steroids. And it doesn’t have to go untreated. At Cohen Medical Center, you’re not just receiving an infusion—you’re receiving the most advanced, targeted care available in autoimmune medicine today. Take control of your health—schedule your consultation with Cohen Medical Center today.
